{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:53:16Z","timestamp":1759837996251,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821"],"award-info":[{"award-number":["OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821","OCC-154821"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institute of Health Research Fellowship","award":["CIHR-FRN# 171259"],"award-info":[{"award-number":["CIHR-FRN# 171259"]}]},{"name":"Research in Addiction Medicine Scholars Program","award":["R25DA033211"],"award-info":[{"award-number":["R25DA033211"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Take-Home Naloxone (THN) is a core intervention aimed at addressing the toxic illicit opioid drug supply crisis. Although THN programs are available in all provinces and territories throughout Canada, there are currently no standardized guidelines\u00a0for THN programs. The Delphi method is a tool for consensus building often used in policy development that allows for engagement of stakeholders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used an adapted anonymous online Delphi method to elicit priorities for a Canadian guideline on THN as a means of facilitating meaningful stakeholder engagement. A guideline development group generated a series of key questions that were then brought to a 15-member voting panel. The voting panel was comprised of people with lived and living experience of substance use, academics specializing in harm reduction, and clinicians and public health professionals from across Canada. Two rounds of voting were undertaken to score questions on importance for inclusion in the guideline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine questions that were identified as most important include what equipment should be in THN kits, whether there are important differences between intramuscular and intranasal naloxone administration, how stigma impacts access to distribution programs, how effective THN programs are at saving lives, what distribution models are most effective and equitable, storage considerations for naloxone in a community setting, the role of CPR and rescue breathing in overdose response, client preference of naloxone distribution program type, and what aftercare should be provided for people who respond to overdoses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Delphi method is an equitable consensus building process that generated priorities to guide guideline development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00650-4","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T10:02:55Z","timestamp":1656756175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Priority setting for Canadian Take-Home Naloxone best practice guideline development: an adapted online Delphi method"],"prefix":"10.1186","volume":"19","author":[{"given":"Max","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Medley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Rittenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas D.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Leece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Elton-Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farihah","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane L.","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane A.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"650_CR1","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Apparent opioid and stimulant toxicity deaths: surveillance of opioid- and stimulant-related harms in Canada [Internet]. Ottawa: Public Health Agency of Canada; 2021 [cited 2021 Sep 9]. Available from: https:\/\/health-infobase.canada.ca\/src\/doc\/SRHD\/UpdateDeathsJune2021.pdf."},{"key":"650_CR2","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.14664","volume":"114","author":"MA Irvine","year":"2019","unstructured":"Irvine MA, Kuo M, Buxton JA, Balshaw R, Otterstatter M, Macdougall L, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114:1602\u201313.","journal-title":"Addiction"},{"key":"650_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14740338.2015.1037274","volume":"14","author":"HK Kim","year":"2015","unstructured":"Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14:1137\u201346.","journal-title":"Expert Opin Drug Saf"},{"key":"650_CR4","unstructured":"Moustaqim-Barrette A, Elton-Marshall T, Leece P, Morissette C, Rittenbach K, Buxton J. Environmental Scan Naloxone access and distribution in Canada. The University of British Columbia; 2019 [cited 2020 Dec 11]. Available from: https:\/\/doi.library.ubc.ca\/10.14288\/1.0379400."},{"key":"650_CR5","doi-asserted-by":"publisher","first-page":"e030046","DOI":"10.1136\/bmjopen-2019-030046","volume":"9","author":"S Young","year":"2019","unstructured":"Young S, Williams S, Otterstatter M, Lee J, Buxton J. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study. BMJ Open. 2019;9:e030046.","journal-title":"BMJ Open"},{"key":"650_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/JAN.0000000000000230","volume":"29","author":"L Chimbar","year":"2018","unstructured":"Chimbar L, Moleta Y. Naloxone effectiveness: a systematic review. J Addict Nurs. 2018;29:167\u201371.","journal-title":"J Addict Nurs"},{"key":"650_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.drugpo.2015.09.011","volume":"26","author":"A McAuley","year":"2015","unstructured":"McAuley A, Aucott L, Matheson C. Exploring the life-saving potential of naloxone: a systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users. Int J Drug Policy. 2015;26:1183\u20138.","journal-title":"Int J Drug Policy"},{"key":"650_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111:1177\u201387.","journal-title":"Addiction"},{"key":"650_CR9","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2468-2667(18)30044-6","volume":"3","author":"MA Irvine","year":"2018","unstructured":"Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018;3:e218\u201325.","journal-title":"Lancet Public Health"},{"key":"650_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599812467004","volume":"148","author":"RM Rosenfeld","year":"2013","unstructured":"Rosenfeld RM, Shiffman RN, Robertson P. Clinical practice guideline development manual, third edition: a quality-driven approach for translating evidence into action. Otolaryngol Neck Surg. 2013;148:S1-55.","journal-title":"Otolaryngol Neck Surg"},{"key":"650_CR11","unstructured":"World Health Organization, Management of Substance Abuse Team, World Health Organization. Community management of opioid overdose. 2014 [cited 2020 Dec 11]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK264311\/."},{"issue":"5","key":"650_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"K Kampman","year":"2015","unstructured":"Kampman K, Jarvis M, FASAM. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358\u201367.","journal-title":"J Addict Med."},{"key":"650_CR13","doi-asserted-by":"publisher","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Preventing opioid overdose deaths with take-home naloxone. LU: Publications Office; 2016 [cited 2021 Nov 11]. Available from: https:\/\/doi.org\/10.2810\/357062.","DOI":"10.2810\/357062"},{"key":"650_CR14","first-page":"347","volume":"153","author":"RT Tsuyuki","year":"2020","unstructured":"Tsuyuki RT, Arora V, Barnes M, Beazely MA, Boivin M, Christofides A, et al. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Can Pharm J Rev Pharm Can. 2020;153:347\u201351.","journal-title":"Can Pharm J Rev Pharm Can"},{"key":"650_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugpo.2017.03.014","volume":"45","author":"T Cameron","year":"2017","unstructured":"Cameron T, Pauly B, Belle-Isle L, Cavalieri W, Elliott R, Strike C, et al. Canadian harm reduction policies: a comparative content analysis of provincial and territorial documents. Int J Drug Policy. 2017;45:9\u201317.","journal-title":"Int J Drug Policy"},{"key":"650_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugpo.2018.12.014","volume":"71","author":"E Hyshka","year":"2019","unstructured":"Hyshka E, Anderson-Baron J, Pugh A, Belle-Isle L, Hathaway A, Pauly B, et al. Principles, practice, and policy vacuums: policy actor views on provincial\/territorial harm reduction policy in Canada. Int J Drug Policy. 2019;71:142\u20139.","journal-title":"Int J Drug Policy."},{"key":"650_CR17","first-page":"655","volume":"38","author":"SS McMillan","year":"2016","unstructured":"McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38:655\u201362.","journal-title":"Int J Clin Pharm"},{"key":"650_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/135581969900400410","volume":"4","author":"N Black","year":"1999","unstructured":"Black N, Murphy M, Lamping D, McKee M, Sanderson C, Askham J, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy. 1999;4:236\u201348.","journal-title":"J Health Serv Res Policy"},{"key":"650_CR19","unstructured":"Adams A, Ferguson M, Greer A, Lock K, Scow M, Burmeister C, et al. Guideline development in harm reduction: considerations around the meaningful involvement of people with lived and living experience. In review."},{"key":"650_CR20","unstructured":"\u201cNothing About Us Without Us\u201d: Greater, meaningful involvement of people who use illegal drugs: a public health, ethical, and human rights imperative. Canadian HIV\/AIDS Legal Network; 2005. Available from: http:\/\/www.hivlegalnetwork.ca\/site\/wp-content\/uploads\/2013\/04\/Greater+Involvement+-+Bklt+-+Drug+Policy+-+ENG.pdf."},{"key":"650_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.2770","author":"D Pourmarzi","year":"2019","unstructured":"Pourmarzi D, Smirnov A, Hepworth J, Rahman T, FitzGerald G, Hall L. Elements of community-based models for treating hepatitis C virus in supporting HCV elimination in Australia: a Delphi study. Int J Health Plann Manag. 2019. https:\/\/doi.org\/10.1002\/hpm.2770.","journal-title":"Int J Health Plann Manag"},{"key":"650_CR22","doi-asserted-by":"publisher","first-page":"103383","DOI":"10.1016\/j.drugpo.2021.103383","volume":"98","author":"R Smart","year":"2021","unstructured":"Smart R, Grant S. Effectiveness and implementability of state-level naloxone access policies: expert consensus from an online modified-Delphi process. Int J Drug Policy. 2021;98:103383.","journal-title":"Int J Drug Policy"},{"key":"650_CR23","unstructured":"Becu A, Allan L. Peer payment standards for short-term engagements [Internet]. Vancouver, Canada: BC Centre for Disease Control; 2018. Available from: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Educational%20Materials\/Epid\/Other\/peer_payment-guide_2018.pdf."},{"key":"650_CR24","doi-asserted-by":"publisher","DOI":"10.32799\/ijih.v16i2.33346","author":"S Levine","year":"2021","unstructured":"Levine S, Medley A, Norton A. Putting indigenous harm reduction to work: developing and evaluating \u201cnot just Naloxone.\u201d Int J Indig Health. 2021. https:\/\/doi.org\/10.32799\/ijih.v16i2.33346.","journal-title":"Int J Indig Health"},{"key":"650_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1609406918776075","author":"A Gerlach","year":"2018","unstructured":"Gerlach A. Thinking and researching relationally: enacting decolonizing methodologies with an indigenous early childhood program in Canada. Int J Qual Methods. 2018. https:\/\/doi.org\/10.1177\/1609406918776075.","journal-title":"Int J Qual Methods"},{"key":"650_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12889-021-10497-2","volume":"21","author":"A Moustaqim-Barrette","year":"2021","unstructured":"Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T, et al. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 2021;21:597.","journal-title":"BMC Public Health."},{"key":"650_CR27","unstructured":"R: The R project for statistical computing. [cited 2021 Dec 22]. Available from: https:\/\/www.r-project.org\/."},{"key":"650_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S J\u00fcnger","year":"2017","unstructured":"J\u00fcnger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31:684\u2013706.","journal-title":"Palliat Med"},{"key":"650_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.socscimed.2019.02.014","volume":"225","author":"MC Kennedy","year":"2019","unstructured":"Kennedy MC, Boyd J, Mayer S, Collins A, Kerr T, McNeil R. Peer worker involvement in low-threshold supervised consumption facilities in the context of an overdose epidemic in Vancouver, Canada. Soc Sci Med. 2019;225:60\u20138.","journal-title":"Soc Sci Med"},{"key":"650_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00453-5","author":"J Boyd","year":"2021","unstructured":"People with Lived Expertise of Drug Use National Working Group, Boyd J. Having a voice and saving lives: a qualitative survey on employment impacts of people with lived experience of drug use working in harm reduction. Harm Reduct J. 2021. https:\/\/doi.org\/10.1186\/s12954-020-00453-5.","journal-title":"Harm Reduct J"},{"key":"650_CR31","unstructured":"Geiger R, Williams S, Buxton JA. Take Home Naloxone program report: review of data to December 2020. Vancouver, Canada: BC Centre for Disease Control; 2021. Available from: https:\/\/towardtheheart.com\/assets\/uploads\/1633447437vVpqLO7FuWUTNsvSE8LxWVo2d8UTqZPLHuqMSro.pdf."},{"key":"650_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00452-8","author":"V Lei","year":"2022","unstructured":"Lei V, Ferguson M, Geiger R, Williams S, Liu L, Buxton JA. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data. Subst Abuse Treat Prev Policy. 2022. https:\/\/doi.org\/10.1186\/s13011-022-00452-8.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"650_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103383","volume":"98","author":"R Smart","year":"2021","unstructured":"Smart R, Grant S. Effectiveness and implementability of state-level naloxone access policies: expert consensus from an online modified-Delphi process. International Journal of Drug Policy. 2021;98:","journal-title":"International Journal of Drug Policy."},{"key":"650_CR34","doi-asserted-by":"publisher","first-page":"103237","DOI":"10.1016\/j.drugpo.2021.103237","volume":"93","author":"F Ali","year":"2021","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;93:103237.","journal-title":"Int J Drug Policy"},{"key":"650_CR35","doi-asserted-by":"publisher","first-page":"e2112865","DOI":"10.1001\/jamanetworkopen.2021.12865","volume":"4","author":"T Gomes","year":"2021","unstructured":"Gomes T, Kitchen SA, Murray R. Measuring the burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e2112865.","journal-title":"JAMA Netw Open"},{"key":"650_CR36","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook. GRADING of Recommendations Assessment, Development and Evaluation (GRADE) Working Group; 2013 [cited 2021 Sep 8]. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.svwngs6pm0f2."},{"key":"650_CR37","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1177\/1049732318782167","volume":"28","author":"KL Matthews","year":"2018","unstructured":"Matthews KL, Baird M, Duchesne G. Using online meeting software to facilitate geographically dispersed focus groups for health workforce research. Qual Health Res. 2018;28:1621\u20138.","journal-title":"Qual Health Res"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00650-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T10:03:53Z","timestamp":1656756233000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00650-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Delphi project within the Guideline development process is not deemed research as per TCPS 2 guidelines (Government of Canada, 2016) as the Guideline Development Group are considered consultants on the project rather than research participants. The Guideline development project was approved by University of British Columbia Research Ethics Board (H19-03958).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}